Open Access Open Access  Restricted Access Subscription Access

Objectives, Etiology, Epidemiology, Patho Physiology, Diagnosis, Differential Diagnosis, Treatment/Management, Prognosis and Complications of Glycogen Storage Disease Type II or Pompes Disease

Muralinath E., Guruprasad M., Madhavi Latha C., Sheethal U., Rajitha V., Manohar U., Srinadh G., Rohitha K.

Abstract


Pompe disease, also known as glycogen storage disease type II, is an uncommon hereditary condition caused by an acid α-glucosidase (GAA) deficiency. This deficiency results in impaired glycogen breakdown within lysosomes, primarily influencing muscular tissue. The disease is inherited in an autosomal recessive pattern and presents in 2 main phenotypes: infantile-onset Pompe disease (IOPD) and late-onset Pompe disease (LOPD).

IOPD is the more severe form, characterized within the first months of life along with hypotonia, hypertrophic cardiomyopathy, respiratory failure, and developmental delays, frequently resulting in early mortality without treatment. LOPD, which emerges in childhood or adulthood, advances more slowly, along with symptoms namely proximal muscle weakness and respiratory insufficiency because of diaphragm involvement, while cardiac issues are rare.

Diagnosis relies on determining decreased GAA enzyme activity, genetic testing, and estimating cross-reactive immunologic material status. Early determination, especially via newborn screening, and timely treatment initiation are critical regarding promotion of outcomes. This activity for healthcare professionals is designed to increase the learner's competence in identifying the clinical features of glycogen storage disease type II, executing the suggested evaluation, and implementing an appropriate interprofessional management approach to promote patient outcomes.

 


Full Text:

PDF

References


van den Hout, H. M., Hop, W., van Diggelen, O. P., Smeitink, J. A., Smit, G. P., Poll-The, B. T., Bakker, H. D., Loonen, M. C., de Klerk, J. B., Reuser, A. J., & van der Ploeg, A. T. (2003). The natural course of infantile Pompe’s disease: 20 original cases compared with 133 cases from the literature. Pediatrics, 112(2), 332–340.

Taverna, S., Cammarata, G., Colomba, P., Sciarrino, S., Zizzo, C., Francofonte, D., Zora, M., Scalia, S., Brando, C., Curto, A. L., Marsana, E. M., Olivieri, R., Vitale, S., & Duro, G. (2020). Pompe disease: Pathogenesis, molecular genetics and diagnosis. Aging (Albany NY), 12(15), 15856–15874.

Lim, J. A., Li, L., & Raben, N. (2014). Pompe disease: From pathophysiology to therapy and back again. Frontiers in Aging Neuroscience, 6, 177.

Güngör, D., & Reuser, A. J. (2013). How to describe the clinical spectrum in Pompe disease? American Journal of Medical Genetics Part A, 161A(2), 399–400.

Filosto, M., Cotelli, M. S., Vielmi, V., Todeschini, A., Rinaldi, F., Rota, S., Scarpelli, M., & Padovani, A. (2014). Late-onset glycogen storage disease type II. Current Molecular Medicine, 14(8), 971–978.

Kishnani, P. S., Goldenberg, P. C., DeArmey, S. L., Heller, J., Benjamin, D., Young, S., Bali, D., Smith, S. A., Li, J. S., Mandel, H., Koeberl, D., Rosenberg, A., & Chen, Y. T. (2010). Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Molecular Genetics and Metabolism, 99(1), 26–33.

Bali, D. S., Goldstein, J. L., Banugaria, S., Dai, J., Mackey, J., Rehder, C., & Kishnani, P. S. (2012). Predicting CRIM status in Pompe disease using GAA mutations. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 160C(1), 40–49.

Wang, Z., Okamoto, P., & Keutzer, J. (2014). A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease. Molecular Genetics and Metabolism, 111(2), 92–100.

Kishnani, P. S., Corzo, D., Leslie, N. D., Gruskin, D., van der Ploeg, A., Clancy, J. P., Parini, R., Morin, G., Beck, M., Bauer, M. S., Jokic, M., Tsai, C. E., Tsai, B. W., Morgan, C., O’Meara, T., Richards, S., Tsao, E. C., & Mandel, H. (2009). Early treatment with alglucosidase alfa prolongs long-term survival of infants with Pompe disease. Pediatric Research, 66(3), 329–335.

Kuo, W. L., Hirschhorn, R., Huie, M. L., & Hirschhorn, K. (1996). Localization and ordering of acid alpha-glucosidase by fluorescence in situ hybridization. Human Genetics, 97(3), 404–406.

Raben, N., Nichols, R. C., Boerkoel, C., & Plotz, P. (1995). Genetic defects in patients with glycogenosis type II. Muscle & Nerve Supplement, 3, S70–S74.

Thirumal Kumar, D., Umer Niazullah, M., Tasneem, S., Judith, E., Susmita, B., George Priya Doss, C., Selvarajan, E., & Zayed, H. (2019). Characterization of missense mutations in GAA causing Pompe disease. Journal of Cellular Biochemistry, 120(3), 3491–3505.

Chien, Y. H., Chiang, S. C., Zhang, X. K., Keutzer, J., Lee, N. C., Huang, A. C., Chen, C. A., Wu, M. H., Huang, P. H., Tsai, F. J., Chen, Y. T., & Hwu, W. L. (2008). Early detection of Pompe disease by newborn screening. Pediatrics, 122(1), e39–e45.

Elenga, N., Verloes, A., Mrsic, Y., Basurko, C., Schaub, R., Cuadro-Alvarez, E., Kom-Tchameni, R., Carles, G., Lambert, V., Boukhari, R., Fahrasmane, A., Jolivet, A., Nacher, M., & Benoist, J. F. (2018). Incidence of infantile Pompe disease in the Maroon population of French Guiana. BMJ Paediatrics Open, 2(1), e000182.

Mechtler, T. P., Stary, S., Metz, T. F., De Jesús, V. R., Greber-Platzer, S., Pollak, A., Herkner, K. R., Streubel, B., & Kasper, D. C. (2012). Neonatal screening for lysosomal storage disorders in Austria. The Lancet, 379(9813), 335–341.

Burton, B. K., Charrow, J., Hoganson, G. E., Waggoner, D., Tinkle, B., Braddock, S. R., Schneider, M., Grange, D. K., Nash, C., Shryock, H., Barnett, R., Shao, R., Basheeruddin, K., & Dizikes, G. (2017). Newborn screening for lysosomal storage disorders in Illinois. The Journal of Pediatrics, 190, 130–135.

Ausems, M. G., Verbiest, J., Hermans, M. P., Kroos, M. A., Beemer, F. A., Wokke, J. H., Sandkuijl, L. A., Reuser, A. J., & van der Ploeg, A. T. (1999). Frequency of glycogen storage disease type II in The Netherlands. European Journal of Human Genetics, 7(6), 713–716.

Thurberg, B. L., Lynch Maloney, C., Vaccaro, C., Afonso, K., Tsai, A. C., Bossen, E., Kishnani, P. S., & O’Callaghan, M. (2006). Pathology after enzyme replacement therapy for Pompe disease. Laboratory Investigation, 86(12), 1208–1220.

Raben, N., Danon, M., Gilbert, A. L., Dwivedi, S., Collins, B., Thurberg, B. L., Mattaliano, R. J., Nagaraju, K., & Plotz, P. H. (2003). Enzyme replacement therapy in the mouse model of Pompe disease. Molecular Genetics and Metabolism, 80(1–2), 159–169.

Meena, N. K., Ralston, E., Raben, N., & Puertollano, R. (2020). Enzyme replacement therapy reverses pathogenic cascade in Pompe disease. Molecular Therapy – Methods & Clinical Development, 18, 199–214.

Sancak, Y., Bar-Peled, L., Zoncu, R., Markhard, A. L., Nada, S., & Sabatini, D. M. (2010). Ragulator–Rag complex targets mTORC1 to lysosomes. Cell, 141(2), 290–303.

Kim, J., Kundu, M., Viollet, B., & Guan, K. L. (2011). AMPK and mTOR regulate autophagy. Nature Cell Biology, 13(2), 132–141.

Winkel, L. P., Hagemans, M. L., van Doorn, P. A., Loonen, M. C., Hop, W. J., Reuser, A. J., & van der Ploeg, A. T. (2005). Natural course of non-classic Pompe disease. Journal of Neurology, 252(8), 875–884.

Kishnani, P. S., Hwu, W. L., Mandel, H., Nicolino, M., Yong, F., & Corzo, D. (2006). Natural history of infantile-onset Pompe disease. The Journal of Pediatrics, 148(5), 671–676.

Reuser, A. J. J., van der Ploeg, A. T., Chien, Y. H., Llerena, J., Abbott, M. A., Clemens, P. R., Kimonis, V. E., Leslie, N., Maruti, S. S., Sanson, B. J., Araujo, R., Periquet, M., Toscano, A., & Kishnani, P. S. (2019). GAA variants and phenotypes in Pompe disease. Human Mutation, 40(11), 2146–2164.

Davison, J. E. (2020). Advances in diagnosis and management of Pompe disease. Journal of Mother and Child, 24(2), 3–8.

Goldstein, J. L., Young, S. P., Changela, M., Dickerson, G. H., Zhang, H., Dai, J., Peterson, D., Millington, D. S., Kishnani, P. S., & Bali, D. S. (2009). Screening for Pompe disease using dried blood spots. Muscle & Nerve, 40(1), 32–36.

Kishnani, P. S., Amartino, H. M., Lindberg, C., Miller, T. M., Wilson, A., & Keutzer, J. (2014). Methods of diagnosis of Pompe disease. Molecular Genetics and Metabolism, 113(1–2), 84–91.

Toscano, A., Montagnese, F., & Musumeci, O. (2013). Early diagnosis in late-onset Pompe disease. Acta Myologica, 32(2), 78–81.

Zhang, H., Kallwass, H., Young, S. P., Carr, C., Dai, J., Kishnani, P. S., Millington, D. S., Keutzer, J., Chen, Y. T., & Bali, D. (2006). Comparison of inhibitors in DBS assays for Pompe disease. Genetics in Medicine, 8(5), 302–306.

Anderson, G., Smith, V. V., Malone, M., & Sebire, N. J. (2005). Blood film examination for vacuolated lymphocytes. Journal of Clinical Pathology, 58(12), 1305–1310.

Pascarella, A., Terracciano, C., Farina, O., Lombardi, L., Esposito, T., Napolitano, F., Franzese, G., Panella, G., Tuccillo, F., La Marca, G., Bernardini, S., Boffo, S., Giordano, A., Di Iorio, G., Melone, M. A. B., & Sampaolo, S. (2018). Vacuolated PAS-positive lymphocytes in Pompe disease. Journal of Cellular Physiology, 233(8), 5829–5837.

Rairikar, M. V., Case, L. E., Bailey, L. A., Kazi, Z. B., Desai, A. K., Berrier, K. L., Coats, J., Gandy, R., Quinones, R., & Kishnani, P. S. (2017). Phenotype of infants identified by newborn screening. Molecular Genetics and Metabolism, 122(3), 99–107.

Peruzzo, P., Pavan, E., & Dardis, A. (2019). Molecular genetics of Pompe disease. Annals of Translational Medicine, 7(13), 278.

Pompe Disease Diagnostic Working Group. (2008). Laboratory diagnosis of Pompe disease. Molecular Genetics and Metabolism, 93(3), 275–281.

Sluiter, W., van den Bosch, J. C., Goudriaan, D. A., van Gelder, C. M., de Vries, J. M., Huijmans, J. G., Reuser, A. J., van der Ploeg, A. T., & Ruijter, G. J. (2012). UPLC–MS/MS assay for Pompe disease biomarkers. Clinical Chemistry, 58(7), 1139–1147.

Chien, Y. H., Lee, N. C., Thurberg, B. L., Chiang, S. C., Zhang, X. K., Keutzer, J., Huang, A. C., Wu, M. H., Huang, P. H., Tsai, F. J., Chen, Y. T., & Hwu, W. L. (2009). Newborn screening improves Pompe disease prognosis. Pediatrics, 124(6), e1116–e1125.

Kishnani, P. S., Corzo, D., Nicolino, M., Byrne, B., Mandel, H., Hwu, W. L., Leslie, N., Levine, J., Spencer, C., McDonald, M., Li, J., Dumontier, J., Halberthal, M., Chien, Y. H., Hopkin, R., Vijayaraghavan, S., Gruskin, D., Bartholomew, D., van der Ploeg, A., … Wraith, J. E. (2007). Recombinant human acid alpha-glucosidase in infantile Pompe disease. Neurology, 68(2), 99–109.

van Gelder, C. M., Poelman, E., Plug, I., Hoogeveen-Westerveld, M., van der Beek, N. A. M. E., Reuser, A. J. J., & van der Ploeg, A. T. (2016). Higher dose alglucosidase alfa in infantile Pompe disease. Journal of Inherited Metabolic Disease, 39(3), 383–390.

Desai, A. K., Li, C., Rosenberg, A. S., & Kishnani, P. S. (2019). Immunological challenges in Pompe disease. Annals of Translational Medicine, 7(13), 285.

Chien, Y. H., Hwu, W. L., & Lee, N. C. (2013). Pompe disease: Early diagnosis and treatment. Pediatrics & Neonatology, 54(4), 219–227.

Yang, C. F., Yang, C. C., Liao, H. C., Huang, L. Y., Chiang, C. C., Ho, H. C., Lai, C. J., Chu, T. H., Yang, T. F., Hsu, T. R., Soong, W. J., & Niu, D. M. (2016). Very early treatment in infantile-onset Pompe disease. The Journal of Pediatrics, 169, 174–180.e1.


Refbacks

  • There are currently no refbacks.